HeartBeam shares are trading higher after the company announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the
HeartBeam shares are trading higher after the company announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.